SciSparc (SPRC) EBITDA Margin (2016 - 2022)
SciSparc (SPRC) posted EBITDA Margin of 140.07% for Q4 2022, up 525.24% sequentially from 32.94% in Q3 2022.
SciSparc (SPRC) EBITDA Margin (2016 - 2022) Analysis & Trends
SciSparc has reported EBITDA Margin for 4 years, with the latest figure at 140.07% in Q4 2022.
- Quarterly EBITDA Margin changed N/A year-over-year to 140.07% in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 733.47% (changed N/A YoY) and the FY2025 annual result came in at 978.27%, down 41809.0% from the prior year.
- EBITDA Margin advanced to 140.07% in Q4 2022 per SPRC's latest filing, from 32.94% in the prior quarter.
- Over five years, EBITDA Margin peaked at 140.07% in Q4 2022 and troughed at 371.05% in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | SciSparc | 836,385.99 | 836,385.99 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 140.07% |
| Sep 30, 2022 | -32.94% |
| Dec 31, 2018 | -371.05% |
| Sep 30, 2018 | 100.00% |
| Jun 30, 2018 | 100.00% |
| Mar 31, 2018 | 100.00% |
| Dec 31, 2017 | -347.74% |
| Sep 30, 2017 | 100.00% |
| Jun 30, 2017 | 100.00% |
| Mar 31, 2017 | 100.00% |
| Sep 30, 2016 | 98.13% |
| Jun 30, 2016 | 101.66% |